drug
CT-95
Phase 1updated 3mo agoby $CNTX Context Therapeutics Inc.
Phase 1community read0 votes
indications
indications
NSCLCColorectal Cancer
all catalysts(0)
nothing on the calendar yet
Trials studying CT-95
News(1)
- Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.fiercebiotech · 14d ago
Data sources
last refreshed 25m ago
Found something off?
comments(0)
5-min edit window · permanent after that